Recent Reports

ICER’s final report on targeted immune modulators for treatment of rheumatoid arthritis. The final report includes a summary of a march 2017 meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC).

View More on this Topic

A draft evidence report assessing the comparative clinical effectiveness and value of crisaborole (Eucrisa™, Pfizer, Inc.) and dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) for treatment of atopic dermatitis. This report is open to public comment for four weeks until April 21st at 5pm CT. More information on submitting public comment is available here.

View More on this Topic

ICER’s final report on disease-modifying therapies for multiple sclerosis. The final report includes a summary of a February 2017 meeting of the California Technology Assessment Forum.

View More on this Topic

ICER’s final report reviewing the comparative clinical effectiveness and value of targeted immunomodulators for treatment of moderate to severe plaque psoriasis. The report includes a summary of voting and policy implications from a November 2016 meeting of the New England CEPAC in Boston, MA.

View More on this Topic

Materials

ICER

Choosing Wisely: Antibiotic Use for Acute Bronchitis

New England CEPAC

Tardive Dyskinesia: Open Input Period

New England CEPAC

Rheumatoid Arthritis: Report-at-a-Glance

New England CEPAC

Rheumatoid Arthritis: Evidence Presentation

CTAF

Chronic Low Back and Neck Pain: Stakeholder List

CTAF

Chronic Low Back and Neck Pain: Draft Scoping Document

CTAF

Chronic Low Back and Neck Pain: Open Input Period

New England CEPAC

Rheumatoid Arthritis: Revised Voting Questions

New England CEPAC

Rheumatoid Arthritis: ICER’s Response to Comments

Midwest CEPAC

Ovarian Cancer: Stakeholder List

CTAF

Multiple Sclerosis: Report-at-a-Glance

ICER

White Paper: Gene Therapy